I agree Prorata, there is only one small biotech which I would touch and it sure does jump around a bit. No shorters would dare to touch CSL IMO because they have too many products and plant improvements in the pipeline and a proven track record of delivering. Does anyone else think CSL might deliver a profit upgrade in January or February perhaps? They have done this before and it seems all their systems are going along nicely right now and IVIG just has insatiable demand and competitors raising prices.
CSL has more upside..., page-66
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.70 |
Change
0.580(0.19%) |
Mkt cap ! $150.6B | |||
| Open | High | Low | Value | Volume |
| $308.37 | $311.70 | $307.33 | $411.6M | 1.374M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $310.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.74 | 904 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |